CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2023—OncoHost has signed an option agreement with BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (Be’er Sheva, Israel), to receive a license for a novel biosensing technology called IcAR, or Immuno-checkpoint Artificial Reporter, developed by researchers from BGU. IcAR biosensing technology measures the binding functionality of PD-1 ligands, PD-L1 and PD-L2, to their receptor, PD-1. The researchers found that assessing the functionality of PD-1 ligands was an effective predictor of identifying who will positively respond to anti-PD-1 treatment.
OncoHost also announced that it presented a poster demonstrating the accuracy of its Prophet biomarker model at the American Society of Clinical Oncology annual meeting, June 2–6, in Chicago. Prophet is a plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide first-line immunotherapy decision-making. The Prophet algorithm is trained on OncoHost’s large-scale clinical trial, PROPHETIC.
OncoHost, 855-950-2112